Perspective Therapeutics Inc [CATX] stock prices are up 3.50% to $3.25 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CATX shares have gain 5.86% over the last week, with a monthly amount drifted -6.34%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Perspective Therapeutics Inc [AMEX: CATX] stock has seen the most recent analyst activity on November 25, 2024, when BofA Securities downgraded its rating to a Neutral and also revised its price target to $5 from $24. Previously, UBS started tracking the stock with Buy rating on October 24, 2024, and set its price target to $20. On October 01, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $25 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $21 on September 25, 2024. BofA Securities initiated its recommendation with a Buy and recommended $24 as its price target on July 25, 2024.
The stock price of Perspective Therapeutics Inc [CATX] has been fluctuating between $2.70 and $19.05 over the past year. Currently, Wall Street analysts expect the stock to reach $21.75 within the next 12 months. Perspective Therapeutics Inc [AMEX: CATX] shares were valued at $3.25 at the most recent close of the market. An investor can expect a potential return of 569.23% based on the average CATX price forecast.
Analyzing the CATX fundamentals
The Perspective Therapeutics Inc [AMEX:CATX] reported sales of 8.84M for trailing twelve months, representing a drop of -82.33%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -159.37%, Pretax Profit Margin comes in at -139.74%, and Net Profit Margin reading is -189.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.26 and Total Capital is -0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.13 points at the first support level, and at 3.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.32, and for the 2nd resistance point, it is at 3.40.
Ratios To Look Out For
It’s worth pointing out that Perspective Therapeutics Inc [AMEX:CATX]’s Current Ratio is 9.60. On the other hand, the Quick Ratio is 9.60, and the Cash Ratio is 8.05. Considering the valuation of this stock, the price to sales ratio is 25.72, the price to book ratio is 0.67.
Transactions by insiders
Recent insider trading involved HENSON HEIDI, Director, that happened on Dec 04 ’24 when 25975.0 shares were purchased. CEO, Spoor Johan M. completed a deal on Dec 04 ’24 to buy 8000.0 shares. Meanwhile, Director Williamson Robert F III bought 6266.0 shares on Nov 25 ’24.
